Telix Pharma Updates China Study, FDA Resubmissions
Ticker: TLPPF · Form: 6-K · Filed: Dec 22, 2025 · CIK: 2007191
| Field | Detail |
|---|---|
| Company | Telix Pharmaceuticals Ltd (TLPPF) |
| Form Type | 6-K |
| Filed Date | Dec 22, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: drug-development, regulatory-filing, clinical-trial, fda
TL;DR
Telix Pharma advancing Illuccix in China, resubmitting FDA applications for TLX101-CDx & TLX250-CDx.
AI Summary
On December 22, 2025, Telix Pharmaceuticals Limited announced updates regarding its precision medicine portfolio. Key developments include the initiation of a Phase 3 study for Illuccix in China, and FDA resubmissions for TLX101-CDx and TLX250-CDx. These advancements are part of Telix's strategy to expand its global reach and product pipeline.
Why It Matters
These updates signal progress in Telix's key drug development programs, potentially impacting future revenue streams and market positioning in the precision medicine sector.
Risk Assessment
Risk Level: medium — Regulatory hurdles and clinical trial outcomes for the mentioned drugs (Illuccix, TLX101-CDx, TLX250-CDx) present inherent risks to Telix Pharmaceuticals' development and commercialization plans.
Key Players & Entities
- Telix Pharmaceuticals Limited (company) — Filer of the 6-K report and subject of the announcement.
- Illuccix (drug) — Product undergoing Phase 3 study in China.
- TLX101-CDx (drug) — Product with an FDA resubmission.
- TLX250-CDx (drug) — Product with an FDA resubmission.
- December 22, 2025 (date) — Date of the announcement filed with the ASX and this 6-K.
- Australian Securities Exchange (company) — Exchange where Telix Pharmaceuticals Limited filed its announcement.
- FDA (company) — Regulatory body for which resubmissions were made.
FAQ
What is the status of the Illuccix Phase 3 study in China?
The announcement indicates that the Illuccix China Phase 3 Study has been initiated.
Which Telix products have had FDA resubmissions?
TLX101-CDx and TLX250-CDx have had FDA resubmissions.
When was this announcement made?
The announcement was made on December 22, 2025.
Where is Telix Pharmaceuticals Limited based?
Telix Pharmaceuticals Limited is based in North Melbourne, Victoria, Australia.
What type of report is this filing?
This filing is a Form 6-K, a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Filing Stats: 238 words · 1 min read · ~1 pages · Grade level 15.4 · Accepted 2025-12-22 06:52:02
Filing Documents
- k6pxupdate.htm (6-K) — 11KB
- pxupdatepr.htm (EX-99.1) — 30KB
- image1.gif (GRAPHIC) — 34KB
- 0002007191-25-000077.txt ( ) — 89KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.           Telix Pharmaceuticals Limited       Date: December 22, 2025 By: /s/ Genevieve Ryan     Name: Genevieve Ryan     Title: Company Secretary